

Submission Data File

General Information	
Form Type*	S-8 POS
Contact Name	
Contact Phone	
Filer File Number*	333-205160
Filer CIK*	0000887151 (Capstone Therapeutics Corp.)
Filer CCC*	*****
Filer is Smaller Reporting Company	Yes
Confirming Copy	No
Notify via Website only	No
Return Copy	No
SROS*	NASD
(End General Information)	

Document Information	
File Count*	1
Document Name 1*	fs8posam_032119.htm
Document Type 1*	S-8 POS
Document Description 1	S-8 POS
(End Document Information)	

Notifications	
Notify via Website only	No
E-mail 1	bdunford@capstonethx.com
E-mail 2	ltaeger@capstonethx.com
E-mail 3	ktutherow@capstonethx.com
E-mail 4	edgar@globenewswire.com
(End Notifications)	

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

**POST-EFFECTIVE AMENDMENT NO. 1 TO
FORM S-8 REGISTRATION STATEMENT**

UNDER THE SECURITIES ACT OF 1933

CAPSTONE THERAPEUTICS CORP.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

86-0585310
(I.R.S. Employer
Identification No.)

1275 W. Washington Street, Suite 104
Tempe, Arizona
(Address of Principal Executive Offices)

85281
(Zip Code)

Capstone Therapeutics Corp. 2015 Equity Incentive Plan

(Full title of the plan)

Les M. Taeger
Senior Vice President, Chief Financial Officer
Capstone Therapeutics Corp.
1275 W. Washington Street, Suite 104
Tempe, AZ 85281

Copy to:
Jacque Westling
Quarles & Brady LLP
Renaissance One, Two North Central Avenue
Phoenix, AZ 85004

(Name and address of agent for service)

(602)-286-5520

(Telephone number, including area code, of agent for service)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

DEREGISTRATION OF SECURITIES

Capstone Therapeutics Corp. (the “Registrant”) is filing this Post-Effective Amendment No. 1 (this “Post-Effective Amendment”) to the Registration Statement on Form S-8, No. 333-205160 (the “Registration Statement”) to terminate the effectiveness of the Registration Statement and to remove from registration all securities that remain unsold under the Capstone Therapeutics Corp. 2015 Equity Incentive Plan.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Tempe, State of Arizona, on March 21, 2019.

CAPSTONE THERAPEUTICS CORP.

By: /s/Les M. Taeger

Les M. Taeger

Senior Vice President and Chief Financial Officer

No other person is required to sign these Post-Effective Amendments on behalf of the Registrant in reliance upon Section 478 of the Securities Act of 1933, as amended.